Physician profile

Veronica Mrowca

Physician Assistant · New York, NY

NPI 1992581847

$485.71

in general payments reported to CMS, 2019-2025

4 companies · $469 in 2025

The $469 reported for 2025 was more than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Food and Beverage$485.71

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Axogen $159.31 2025
Motiva USA, LLC $159.30 2025
Solventum Corporation $150.00 2025 V.A.C.Ulta
Davol INC. $17.10 2024 Phasix Mesh

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Veronica Mrowca

$485.71

in general payments reported 2019-2025

Years
2024-2025
Top company
Axogen
Context
The $469 reported for 2025 was more than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).

https://glasscript.com/doctor/11570629/veronica-mrowca

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.